CN101896819A - 对癌症的诊断测试、预测测试和预后测试 - Google Patents

对癌症的诊断测试、预测测试和预后测试 Download PDF

Info

Publication number
CN101896819A
CN101896819A CN2008801209233A CN200880120923A CN101896819A CN 101896819 A CN101896819 A CN 101896819A CN 2008801209233 A CN2008801209233 A CN 2008801209233A CN 200880120923 A CN200880120923 A CN 200880120923A CN 101896819 A CN101896819 A CN 101896819A
Authority
CN
China
Prior art keywords
cancer
biomarker
level
predetermined value
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801209233A
Other languages
English (en)
Chinese (zh)
Inventor
K·斯托伯
G·H·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Cancer Diagnostics Ltd
Original Assignee
Cambridge Cancer Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Cancer Diagnostics Ltd filed Critical Cambridge Cancer Diagnostics Ltd
Publication of CN101896819A publication Critical patent/CN101896819A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2008801209233A 2007-10-15 2008-10-15 对癌症的诊断测试、预测测试和预后测试 Pending CN101896819A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0720113.0 2007-10-15
GBGB0720113.0A GB0720113D0 (en) 2007-10-15 2007-10-15 Diagnostic, prognostic and predictive testing for cancer
PCT/GB2008/003501 WO2009050461A1 (en) 2007-10-15 2008-10-15 Diagnostic, predictive and prognostic testing for cancer

Publications (1)

Publication Number Publication Date
CN101896819A true CN101896819A (zh) 2010-11-24

Family

ID=38813827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801209233A Pending CN101896819A (zh) 2007-10-15 2008-10-15 对癌症的诊断测试、预测测试和预后测试

Country Status (11)

Country Link
US (3) US8512716B2 (https=)
EP (1) EP2208070B1 (https=)
JP (2) JP5559056B2 (https=)
CN (1) CN101896819A (https=)
AU (1) AU2008313459B2 (https=)
CA (1) CA2702653A1 (https=)
DK (1) DK2208070T3 (https=)
ES (1) ES2395890T3 (https=)
GB (1) GB0720113D0 (https=)
PT (1) PT2208070E (https=)
WO (1) WO2009050461A1 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
CN105324670A (zh) * 2013-05-09 2016-02-10 宝洁公司 用于评估健康状况的方法和系统
CN106834462A (zh) * 2016-06-15 2017-06-13 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344868A (zh) * 2018-01-23 2018-07-31 郑州大学第附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN108344867A (zh) * 2018-01-23 2018-07-31 郑州大学第附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN109988708A (zh) * 2019-02-01 2019-07-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
CN113474659A (zh) * 2018-12-20 2021-10-01 阿奎尔诊断有限公司 Mcm5作为妇科癌症标记物的用途
CN114019163A (zh) * 2021-11-02 2022-02-08 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途
CN114717312A (zh) * 2015-02-17 2022-07-08 浙江数问生物技术有限公司 用于膀胱癌分子亚型分型的方法和试剂盒

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921873D0 (en) * 2009-12-15 2010-01-27 Cytosystems Ltd Assay
WO2012012693A2 (en) * 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
US9857354B2 (en) 2014-06-01 2018-01-02 Novazoi Theranostics, Inc. Compositions and methods for prognosis and treatment of neoplasm
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
CN110846413B (zh) * 2019-11-23 2023-05-26 中南大学湘雅三医院 Mafg/mafg-as1/mafg正反馈环作为靶位点检测试剂的应用
WO2023150578A2 (en) * 2022-02-01 2023-08-10 4D Path Inc. Systems and methods for image-based disease characterization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146513A1 (en) * 1999-04-01 2004-07-29 Dakocytomation Denmark A/S Monoclonal antibodies against human protein Mcm3, process for their production, and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329177A1 (de) * 1993-08-30 1995-03-02 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Serin-Threonin-Kinasen
EP1422526A1 (en) 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
GB0323225D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer classification
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2563168A1 (en) * 2004-04-14 2005-11-17 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
EP1805676A1 (en) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
ATE464395T1 (de) * 2005-02-18 2010-04-15 Astrazeneca Ab Verfahren zur bestimmung der reaktionsfähigkeit gegenüber chk1-inhibitoren
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
ATE456053T1 (de) * 2005-12-30 2010-02-15 Ventana Med Syst Inc Na+, k+-atpase-expression bei zervixdysplasie und krebs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146513A1 (en) * 1999-04-01 2004-07-29 Dakocytomation Denmark A/S Monoclonal antibodies against human protein Mcm3, process for their production, and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SCOTT I S等: "Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: Applications in diagnostic neuropathology", 《NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY》 *
任占平: "微小染色体维持蛋白与肿瘤", 《诊断病理学杂志》 *
王永 等: "利用MCM2检测细胞的增殖性在大肠肿瘤诊断中的应用", 《中国普外基础与临床杂志》 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324670A (zh) * 2013-05-09 2016-02-10 宝洁公司 用于评估健康状况的方法和系统
CN103592444A (zh) * 2013-11-27 2014-02-19 中国人民解放军沈阳军区总医院 一种检测乳腺癌中cyclin G1蛋白表达并进行预后评估的方法
CN114717312A (zh) * 2015-02-17 2022-07-08 浙江数问生物技术有限公司 用于膀胱癌分子亚型分型的方法和试剂盒
CN114717312B (zh) * 2015-02-17 2024-04-26 浙江数问生物技术有限公司 用于膀胱癌分子亚型分型的方法和试剂盒
CN106834462A (zh) * 2016-06-15 2017-06-13 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN106834462B (zh) * 2016-06-15 2020-11-06 南京卡迪睿伯生物技术有限公司 一组胃癌基因的应用
CN108344868A (zh) * 2018-01-23 2018-07-31 郑州大学第附属医院 人组蛋白H3 Ser10和Ser28在鉴定人早期胚胎的发育分期中的应用
CN108344867A (zh) * 2018-01-23 2018-07-31 郑州大学第附属医院 人组蛋白H3 Ser10和Ser28在鉴定人卵母细胞成熟分期中的应用
CN111187833A (zh) * 2018-11-14 2020-05-22 上海生物芯片有限公司 Plk1和bub1b基因联合作为肺癌生物标志物的用途
CN113474659A (zh) * 2018-12-20 2021-10-01 阿奎尔诊断有限公司 Mcm5作为妇科癌症标记物的用途
CN109988708A (zh) * 2019-02-01 2019-07-09 碳逻辑生物科技(中山)有限公司 一种用于对患有结肠直肠癌的患者进行分型的系统
CN114019163A (zh) * 2021-11-02 2022-02-08 复旦大学附属中山医院 基于活化b细胞表达的结肠癌预后诊断用标记物及其用途

Also Published As

Publication number Publication date
US8512716B2 (en) 2013-08-20
US20140154680A1 (en) 2014-06-05
PT2208070E (pt) 2013-01-08
CA2702653A1 (en) 2009-04-23
EP2208070A1 (en) 2010-07-21
GB0720113D0 (en) 2007-11-28
DK2208070T3 (da) 2012-12-17
US20180223366A1 (en) 2018-08-09
JP2014095726A (ja) 2014-05-22
AU2008313459A1 (en) 2009-04-23
ES2395890T3 (es) 2013-02-15
JP5837630B2 (ja) 2015-12-24
US20100285474A1 (en) 2010-11-11
EP2208070B1 (en) 2012-10-03
WO2009050461A1 (en) 2009-04-23
JP5559056B2 (ja) 2014-07-23
AU2008313459B2 (en) 2013-01-24
JP2011501809A (ja) 2011-01-13

Similar Documents

Publication Publication Date Title
JP5837630B2 (ja) ガンの診断、予測、および予後試験
Knösel et al. TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t (X; 18): analysis of 319 cases
Wang et al. BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers
Bayraktar et al. USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer
US20140322705A1 (en) Cancer diagnostic and cancer therapeutic
Gaber et al. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC
Li et al. Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
WO2010009171A2 (en) Src activation for determining cancer prognosis and as a target for cancer therapy
WO2011047019A1 (en) An objective, quantitative method to predict histological subtype in non-small cell lung cancer
KR20250060189A (ko) Atr/chk1 신호전달 경로 저해제를 사용하여 질환을 치료하는 방법 및 시스템
Guo et al. Potential markers to differentiate uterine leiomyosarcomas from leiomyomas
LaBuda et al. ARID1A: Gene, protein, and function in endometrial cancer
Li et al. RETRACTED ARTICLE: Octamer transcription factor 1 mediates epithelial-mesenchymal transition in colorectal cancer
Mamat@ Yusof et al. Gene expression and soluble protein level of PD-1 and its ligands (PD-L1 and PD-L2) in endometrial cancer
Yakirevich et al. Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer
Xin et al. p-CREB-1 at Ser 133 is a potential marker for breast cancer.
JP6936231B2 (ja) 転移性去勢抵抗性前立腺癌（ｍＣＲＰＣ）患者における治療選択のためのバイオマーカーとしてのアンドロゲン受容体バリアント７
Hunt et al. Extensive intratumor proteogenomic heterogeneity revealed by multiregion sampling in high-grade serous Ovarian tumor specimens
Du et al. Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A, cyclin A and cyclin E in invasive ductal breast carcinomas
Xu et al. Expression of WD repeat domain 5 (WDR5) is associated with progression and reduced prognosis in papillary thyroid carcinoma
Liu et al. Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells
Davidson et al. The diagnostic role of PTEN and ARID1A in serous effusions
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
JP2009524048A (ja) Ｓｈｃタンパク質を使用して消化管および他の癌の再発の予後を診断するための方法
Makise et al. HMGA2 expression in CIC‐rearranged sarcoma and other small round/epithelioid cell tumours

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20101124